Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × betrixaban × Classical hematology × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Venous Thromboembolism 1

Interventions

Epoetin Alfa 35 Darbepoetin alfa 26 epoetin beta 10 Rivaroxaban 9 eltrombopag 5 Heparin, Low-Molecular-Weight 5 pegfilgrastim 4 olaparib 4 emicizumab 4 apixaban 4 Gemcitabine 4 Filgrastim 4 Dalteparin 4 Cyclophosphamide 4 romiplostim 3 pegylated granulocyte colony-stimulating factor 3 peginesatide 3 luspatercept 3 hematide 3 Vancomycin 3 Enoxaparin 3 Azacitidine 3 AP 1903 reagent 3 ACE-011 3 venetoclax 2 roxadustat 2 hetrombopag 2 fludarabine phosphate 2 fludarabine 2 ferric carboxymaltose 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01583218 2023-08-07

APEX

Alexion Pharmaceuticals, Inc.

Phase 3 Completed

7,513 enrolled 18 charts 1 FDA

Classical hematology

Venous Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon ⚡